Evidence map›Paper›PMID 38115677›Full record

ArticleThoracic cancer2024

Prognostic, immunity, stemness, and anticancer drug sensitivity characterization of pyroptosis related genes in non-small cell lung cancer.

Cong Xu, Hongming Ma, Jiawen Chen, Xincheng Li, Zhina Wang, Bin Hu, Nan Zhang, Fanjie Meng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Cong XuDepartment of Thoracic Surgery, Peking University Shougang Hospital, Beijing, China.
Hongming MaDepartment of Respiratory and Critical Care, Emergency General Hospital, Beijing, China.
Jiawen ChenBeijing Institute of Lifeomics, Beijing, China.
Xincheng LiDepartment of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Zhina WangDepartment of Respiratory and Critical Care, Emergency General Hospital, Beijing, China.
Bin HuDepartment of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Nan ZhangDepartment of Respiratory and Critical Care, Emergency General Hospital, Beijing, China.
Fanjie MengDepartment of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-0783-1961
Beijing Emergency Medical Center · CNCapital Medical University · CNGrandomics (China) · CNPeking University Shougang Hospital · CN

Funding

Beijing Postdoctoral Research Foundation 2023-ZZ-042Clinical Research Incubation Project, Beijing Chao Yang Hospital, Capital Medical University CYFH202324Reform and Development Program of Beijing Institute of Respiratory Medicine Ggyfz202325Scientific Research Project of Tianjin Educational Committee 2022KJ273the Medical Research and Development Fund of Emergency General Hospital K202110Wu Jieping Medical Foundation 320.6750.19089-55
6 · The paper itself

Abstract

backgroundPyroptosis plays a pivotal role in the tumor immune microenvironment (TME) dynamics, particularly in non-small cell lung cancer (NSCLC). The aim of our study was to explore its effects on tumor progression, TME patterns, and the efficacy of therapeutic interventions in NSCLC.

methodsOur investigation encompassed a thorough analysis of pyroptosis-related genes (PRGs), integrating immunohistochemistry (IHC) data, TME characteristics, stemness indices, and anticancer drug sensitivities. We aimed to analyze mRNA expression profiles across various cancers, constructing benchmark datasets to assess the clinical significance of PRGs in NSCLC. This included evaluating their association with clinical responses and efficacy. Notably, both our and HPA IHC data demonstrated significantly elevated GSDMD-N protein levels in lung squamous cell carcinoma (LUSC) tissues.

resultsThe expression of PRGs differed significantly between tumor and normal tissues across various cancers, as validated by IHC data, and was correlated with prognosis (p < 0.05). Moreover, our investigation revealed significant differences (p < 0.05) in the expression of the PRGs among distinct TME subtypes categorized as C1 (wound healing), C3 (inflammatory), C2 (IFN-gamma dominant), C5 (immunological quiet), C4 (lymphocyte deficient), and C6 (TGF-beta dominant). Additionally, our research on anticancer drug sensitivity uncovered compelling connections between specific anticancer medications and the expression of PRGs, including GSDMD, ELANE, IL18, and CHMP4A (p < 0.05).

conclusionOur study provided valuable insights into the critical role of PRGs in TME modulation, tumor stemness, and anticancer drug sensitivity across diverse cancers. Our findings illuminate the intricate relationship between pyroptosis and the TME, offering new perspectives for enhancing NSCLC treatment and prognosis.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansPrognosisPyroptosisTumor MicroenvironmentAntineoplastic Agentsanticancer drug sensitivitynon-small cell lung cancerpyroptosisstemness scoretumor microenvironment

Identifiers

PMID38115677
PMCPMC10803221
OpenAlexW4390011111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.